![]() Hugin is currently Chair of the Board of the Garden State Initiative, a nonpartisan research and educational organization focused on economic issues in New Jersey. Hugin also serves as a Director of Chubb Limited, Member of the Board of Trustees of Princeton University and Chair of The Darden School Foundation, University of Virginia. ![]() We are indeed fortunate to have Bob's extraordinary business and financial expertise to help guide Biohaven in advancing novel therapies to patients suffering from disabling neuroscience conditions." ![]() His impressive industry experience with high growth companies, strategic insight and passion for improving the lives of patients will be an asset to Biohaven in this time of significant growth as we continue to successfully commercialize our first product and advance our late-stage development portfolio. Vlad Coric, M.D., Chief Executive Officer of Biohaven commented, "Biohaven is honored to welcome Bob to our Board of Directors. I look forward to being part of Biohaven's future success and working closely with Vlad and the rest of the Board." I hope to help transform Biohaven from a development company to a high growth commercial organization with multiple future products addressing large unmet needs in the neuroscience area. Biohaven has achieved impressive progress in its portfolio development since becoming a public company and is now successfully commercializing NURTEC ODT, its first product, for migraine. Hugin stated, "Neuroscience remains one of the most important areas for drug development given the high burden of disability from diseases like Alzheimer's disease, rare neurologic indications, neuropsychiatric disorders and migraine. He is a noted health expert, who advocated for the importance of business development collaborations, innovations in science and improved patient access. Under his leadership, Celgene saw unprecedented results across all facets of the company and grew by over $30 billion in market capitalization. Until his retirement in 2018, he was the Chairman of the Board of Directors, serving as Executive Chairman from 2016 to 2018. Hugin joined Celgene in 1999 as Chief Financial Officer and served in positions of increasing responsibility during his 19-year tenure with the company, including Executive Chairman, Chief Executive Officer, President and Chief Operating Officer. Having access to Bob's astute business and financial acumen will help Biohaven achieve our goal of becoming the leading pharmaceutical company focused on neuroscience indications." Declan Doogan, M.D., Chairman of Biohaven's Board of Directors, commented, "We are excited to welcome Bob to Biohaven's Board of Directors as we have evolved to a commercial organization and look to the future. ![]()
0 Comments
Leave a Reply. |